Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + cobimetinib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of three distinct agents: 1. **Atezolizumab (Tecentriq)**: A humanized IgG monoclonal antibody that binds to PD-L1, preventing its interaction with PD-1 and B7-1. This removes inhibition of immune responses, enhancing T-cell activity against tumor cells[6][10]. 2. **Cobimetinib (Cotellic)**: A targeted therapy that works as a MEK inhibitor. 3. **Nab-paclitaxel (Abraxane)**: A form of paclitaxel bound to albumin protein, which is a chemotherapy agent. The combination has been studied in clinical trials, including the Phase II COLET study for first-line treatment of patients with cancer[1]. This regimen represents a multi-modal approach combining immunotherapy (atezolizumab), targeted therapy (cobimetinib), and chemotherapy (nab-paclitaxel).
- Other names
- cobimetinib plus atezolizumab plus nab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)CD274 (Programmed cell death protein 1 ligand 1)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on atezolizumab + cobimetinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + cobimetinib + nab-paclitaxel.